Inside Innovation

Out of the 11 biotech companies entering the public market in the last year, eight have been from Washington state. Just this summer, three companies,

Washington-based biotech company, Bristol Myers Squibb, has received a December 23rd decision date from the FDA. If passed, Orencia, a drug originally approved for patients

Real estate investment into the life sciences reached more than $9 billion in the first half of 2021, signaling a potential record-breaking year for industry

Washington is the third cleanest state in the U.S. according to a recent study by Filter King, an air filter delivery company The results of

Last week, Sonoma Biotherapeutics announced it raised $265 million to expand both its Seattle and San Francisco operations. One of the many perks of having

After announcing its new location in Redmond, Washington last week, Evotec says their first order of business in the new 130,000-square-foot campus is to develop

In a partnership with Google, Seattle-based company Lumen BioScience can now use machine learning as a tool to expedite and streamline production of its plant-based

Last week, Seagen, a Washington-based biotech company, announced a deal with China-based RemeGen Co., Ltd. The deal, valued at $2.6 billion, allows Seagen to develop

Washington’s life science industry is thriving. In 2021 so far, almost 50 biotech companies have gone public across the U.S., with several headquartered in the

This week, Life Science Washington announced its president and CEO, Dr. Leslie Alexandre, will retire at the end of 2021. “Dr. Alexandre has been instrumental

Several Seattle-area vaccine scientists shifted their studies to focus on COVID-19 research in the past 18 months. This field of study continues to build on

Icosavax stocks are performing well amidst the Seattle-based companies new public offering. On its first day as a publicly traded company, Icosavax shares skyrocketed by